What is Cell Microsystems?
Cell Microsystems specializes in the development of advanced instrumentation for the imaging, sorting, and isolation of individual cells and colonies. Their flagship product, the CellRaft AIR System, represents a significant leap in clonal outgrowth technology, enabling researchers to perform high-precision analysis in 3D cell culture environments. By automating complex workflows, the company addresses the critical bottlenecks in stem cell biology and cancer research, providing the high-throughput capabilities necessary for modern drug discovery and genomic studies. Their market position is bolstered by a commitment to technical excellence, serving a diverse clientele that ranges from boutique research labs to large-scale pharmaceutical enterprises.
How much funding has Cell Microsystems raised?
Cell Microsystems has raised a total of $14.6M across 4 funding rounds:
Grant
$1.5M
Debt
$150K
Debt
$292K
Other Financing Round
$12.7M
Grant (2018): $1.5M, investors not publicly disclosed
Debt (2020): $150K led by PPP
Debt (2021): $292K supported by PPP
Other Financing Round (2021): $12.7M featuring Telegraph Hill Partners
Key Investors in Cell Microsystems
Telegraph Hill Partners
Telegraph Hill Partners is a San Francisco-based private equity firm that focuses on providing growth capital to commercial-stage companies within the life science, medical technology, and healthcare sectors.
PPP
Public-Private Partnership
Undisclosed Investor
A strategic partner participating in the latest financing round to bolster the company's market expansion and product development efforts.
What's next for Cell Microsystems?
With the recent infusion of $0, Cell Microsystems is poised to accelerate its commercial expansion and R&D initiatives. The strategic focus will likely center on scaling the adoption of the CellRaft AIR System across international markets, while simultaneously enhancing the automation features of their existing product suite. As the demand for precise cellular data grows in the context of personalized medicine and gene therapy, the company is well-positioned to capitalize on these trends. Future growth will be driven by the integration of AI-driven imaging analytics and the expansion of their footprint in the rapidly evolving landscape of 3D cell culture, ensuring sustained competitive advantage in the life science technology ecosystem.
See full Cell Microsystems company page
